<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">University of Birmingham Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Marianne</forename><forename type="middle">;</forename><surname>Weigel</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Clinical Endocrinology</orgName>
								<orgName type="institution" key="instit1">Charité Campus Mitte</orgName>
								<orgName type="institution" key="instit2">Charité University Medicine Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefanie</forename><forename type="middle">;</forename><surname>Hahner</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Internal Medicine I</orgName>
								<orgName type="laboratory">Endocrinology &amp; Diabetes Unit</orgName>
								<orgName type="institution">University Hospital of Wuerzburg</orgName>
								<address>
									<settlement>Wuerzburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mark</forename><forename type="middle">;</forename><surname>Sherlock</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Endocrinology and Diabetes</orgName>
								<orgName type="institution" key="instit1">Adelaide and Meath Hospitals</orgName>
								<orgName type="institution" key="instit2">Incorporating the National Children&apos;s Hospital and Trinity College</orgName>
								<orgName type="institution" key="instit3">Tallaght Hospital</orgName>
								<address>
									<settlement>Dublin</settlement>
									<country key="IE">Ireland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Amar</forename><forename type="middle">;</forename><surname>Agha</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Department of Endocrinology</orgName>
								<orgName type="department" key="dep2">RCSI Medical School</orgName>
								<orgName type="institution">Beaumont Hospital</orgName>
								<address>
									<country>Dublin Ireland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lucy</forename><forename type="middle">Ann</forename><surname>Behan</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Endocrinology and Diabetes</orgName>
								<orgName type="institution" key="instit1">Adelaide and Meath Hospitals</orgName>
								<orgName type="institution" key="instit2">Incorporating the National Children&apos;s Hospital and Trinity College</orgName>
								<orgName type="institution" key="instit3">Tallaght Hospital</orgName>
								<address>
									<settlement>Dublin</settlement>
									<country key="IE">Ireland</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Department of Endocrinology</orgName>
								<orgName type="department" key="dep2">RCSI Medical School</orgName>
								<orgName type="institution">Beaumont Hospital</orgName>
								<address>
									<country>Dublin Ireland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><surname>Ann</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Paul</forename><forename type="middle">;</forename><surname>Stewart</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Wiebke</forename><forename type="middle">;</forename><surname>Arlt</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Institute of Metabolism and Systems Research</orgName>
								<orgName type="institution">University of Birmingham</orgName>
								<address>
									<settlement>Birmingham</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">Centre for Endocrinology, Diabetes and Metabolism</orgName>
								<orgName type="institution">Birmingham Health Partners</orgName>
								<address>
									<settlement>Birmingham</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Daniela</forename><forename type="middle">;</forename><surname>Beier</surname></persName>
							<affiliation key="aff7">
								<orgName type="laboratory">Endocrinology in Charlottenburg</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kathrin</forename><forename type="middle">;</forename><surname>Frey</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Internal Medicine I</orgName>
								<orgName type="laboratory">Endocrinology &amp; Diabetes Unit</orgName>
								<orgName type="institution">University Hospital of Wuerzburg</orgName>
								<address>
									<settlement>Wuerzburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kathrin</forename><forename type="middle">;</forename><surname>Zopf</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Clinical Endocrinology</orgName>
								<orgName type="institution" key="instit1">Charité Campus Mitte</orgName>
								<orgName type="institution" key="instit2">Charité University Medicine Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Marcus</forename><surname>Quinkler</surname></persName>
							<email>marcusquinkler@t-online.de</email>
							<affiliation key="aff0">
								<orgName type="department">Clinical Endocrinology</orgName>
								<orgName type="institution" key="instit1">Charité Campus Mitte</orgName>
								<orgName type="institution" key="instit2">Charité University Medicine Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="laboratory">Endocrinology in Charlottenburg</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Paul</forename><forename type="middle">M</forename><surname>Stewart</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Endocrinology</orgName>
								<orgName type="institution">University Of Leeds</orgName>
								<address>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="laboratory">Endocrinology in Charlottenburg Stuttgarter Platz 1</orgName>
								<address>
									<postCode>10627</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">University of Birmingham Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">527726F4A3EAF4C752ECF9DD2981F466</idno>
					<idno type="DOI">10.1111/cen.13302</idno>
					<note type="submission">Eligibility for repository: Checked on 11/1/2017 This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:40+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>cortisol</term>
					<term>cortisol binding globulin</term>
					<term>adrenal insufficiency</term>
					<term>ACC</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Declaration of interest: M Quinkler and S Hahner worked as a consultant for ViroPharma and had received honoraria for talks.</s><s>M Quinkler received research grants from HRA pharma for studies regarding mitotane.</s><s>M Sherlock has worked as a consultant and received honoraria for talks from Shire.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>• Users may freely distribute the URL that is used to identify this publication.</s></p><p><s>• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.</s></p><p><s>• User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) • Users may not further distribute the material nor use it for the purposes of commercial gain.</s></p><p><s>Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.</s></p><p><s>When citing, please reference the published version.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Take down policy</head><p><s>While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Adrenocortical cancer (ACC) is a rare malignancy that occurs in approximately 0.5-2 per million persons per year <ref type="bibr">1;2</ref> .</s><s>The only curative treatment is radical surgery <ref type="bibr" target="#b2">3</ref> .</s><s>However, even after initial curative surgery, 80% of the patients develop recurrent disease within two years <ref type="bibr" target="#b3">4</ref> .</s><s>Adrenolytic therapy with mitotane (o'p'-DDD) is the established adjuvant therapy for ACC patients after R0 resection <ref type="bibr" target="#b4">5</ref> and also the primary treatment for patients with advanced ACC (3), either as monotherapy or in combination with cytotoxic chemotherapy.</s><s>Mitotane has been shown to extend disease-free survival in retrospective analyses <ref type="bibr">6;7</ref> .</s><s>Recent data shows that mitotane confers adrenolytic activity and down-regulation of steroidogenesis by lipid-induced ER-stress through inhibition of the activity of SOAT-1 <ref type="bibr" target="#b7">8</ref> .</s><s>As mitotane affects all adrenocortical steroid production it is necessary to replace glucocorticoids and sometimes mineralocorticoids in treated patients.</s><s>However, mitotane is a strong inducer of hepatic cytochrome CYP3A4 activity <ref type="bibr">9;10</ref> , which inactivates cortisol to 6βhydroxycortisol.</s><s>Mitotane also increases cortisol binding globulin (CBG) <ref type="bibr" target="#b10">11</ref> .</s><s>These effects result in both a significantly increased cortisol metabolism and reduced free, active cortisol <ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref> .</s><s>Therefore, classic hydrocortisone replacement doses of 20 mg/day, as used in adrenal insufficiency, are not sufficient in ACC patients on mitotane and higher dosages (40-80mg/day) are necessary.</s></p><p><s>A modified-release hydrocortisone preparation (Plenadren©, formerly known as Duocort®), <ref type="bibr">17;18</ref> , is available across Europe for replacement therapy in adult patients with adrenal insufficiency.</s><s>It is administered in the morning and contains a rapidrelease part and a delayed released part of hydrocortisone suggesting that only a once daily dose of hydrocortisone might be necessary.</s><s>Improvement in QoL, blood pressure and metabolic parameters was demonstrated in 64 patients with Addison's disease <ref type="bibr" target="#b19">19</ref> .</s><s>In an open, prospective trial in Addison patients modified-release hydrocortisone decreased BMI and HbA1c compared with immediate release HC treatment <ref type="bibr" target="#b20">20</ref> .</s></p><p><s>Patients with ACC on mitotane treatment often suffer from significant impairment by the disease and associated treatment.</s><s>The number of tablets that need to be ingested is mostly high, making it desirable to reduce their amount.</s><s>The rapid metabolic inactivation of cortisol during mitotane treatment may not only increase the dose of hydrocortisone needed to be taken but also necessitate shortening the time intervals between the doses.</s><s>Thus, a modified-release hydrocortisone might be a useful alternative in this patient group.</s><s>However, although authorized for the use in patients with ACC, it is unclear how concurrent mitotane treatment influences the pharmacokinetic profile of modified-release hydrocortisone.</s><s>Besides increased metabolic inactivation by CYP3A4 induction, gastrointestinal side effects that can be associated with mitotane treatment may represent a further safety issue in this patient group.</s><s>Of note, even for immediate release hydrocortisone, detailed data regarding serum pharmacokinetics in mitotane treated ACC patients is not available.</s></p><p><s>In a series of ACC patients in whom modified release hydrocortisone was considered as alternative treatment to immediate release hydrocortisone, we carried out 24-h pharmacokinetic measurements comparing cortisol (serum and saliva), free serum cortisol and plasma ACTH levels during one day of immediate release hydrocortisone and modified-release hydrocortisone, respectively, both administered at a dose of 40 mg first thing in the morning and 20 mg at lunchtime.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Population</head><p><s>Nine adult patients with histologically confirmed ACC on stable mitotane treatment for at least 4 months in whom alternative replacement therapy with modified release hydrocortisone was considered, were investigated.</s><s>ENS@T stage at diagnosis was 2 (n=8) and 3 (n=1).</s><s>The reason for mitotane treatment was adjuvant therapy (n=5) or metastatic disease (n=4; abdominal lymph nodes and lung) treatment.</s><s>All patients had an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 and no signs of severe renal or hepatic insufficiency.</s><s>None of the patients had other concomitant anticancer treatment except from mitotane.</s><s>However, two patients had received streptozotocin chemotherapy at an earlier stage.</s><s>Immediate release hydrocortisone replacement therapy was taken for at least 4 months prior to the pharmacokinetic assessment.</s><s>No patient received supplementary mineralocorticoid treatment.</s><s>No patient experienced signs of hypocortisolism at time of investigation.</s></p><p><s>Six patients had mitotane plasma levels within the proposed therapeutic range (14-20mg/l), three patients had levels below this range (6.6-9.6mg/l).</s><s>Immediate release and modified release hydrocortisone are freely available for treatment of patients with adrenal insufficiency in Germany.</s><s>All patients provided written informed consent for additional evaluation of blood, saliva and urine samples.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Design and assessments</head><p><s>On study day 1, ACC patients on mitotane treatment were taking 60mg conventional hydrocortisone (40-20-0mg), during study day 2 they took the same dose of modifiedrelease hydrocortisone (40-20-0mg).</s><s>On both days the timing of hydrocortisone tablet intake was 8:00h and 12:00h.</s><s>Mitotane tablets were taken during meal times at 9:00 and 13:00.</s><s>Blood and saliva samples were taken at 7:30, 8:00, 9:00, 10:00, 11:00, 12:00, 13:00, 14:00, 15:00, 16:00, 17:00.</s><s>Saliva samples were collected with the Salivette system (Sarstedt, Etten-Leur, The Netherlands) in accordance with the manufacturer´s instructions.</s></p><p><s>24-hour urines were collected for analysis of urinary cortisol metabolites two weeks prior to the pharmacokinetic measurements while the patients were on 60mg conventional hydrocortisone (40-20-0mg).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Laboratory Measurements</head><p><s>Serum cortisol was measured by a solid-phase competitive chemiluminescent enzyme immunoassay (Siemens Healthcare, Erlangen, Germany), with an analytical sensitivity of 5.5 nmol/l (0.2 µg/dl).</s><s>The intra-and interassay coefficients of variability (CVs) of the cortisol assay were 6.9% and 7.3%, respectively.</s><s>Plasma ACTH was measured by a solid-phase, two-site sequential chemiluminescent assay (Siemens Healthcare).</s><s>The intra-and interassay CVs were 9.6% and 8.8%, respectively.</s><s>Salivary cortisol was analysed by electrochemiluminescence immunoassay (ECLIA) (Roche Diagnostics, Germany).</s></p><p><s>Serum CBG was measured by radioimmunoassay (MyBioSource, San Diego, California, USA).</s><s>The intra-and interassay coefficients of variability (CVs) of the CBG RIA assay 3.9% and 5.5%, respectively.</s><s>Calculated free cortisol was derived using the Coolens' equation: U2</s></p><formula xml:id="formula_0">× K (1 + N) + U × [1 + N + K(T − C)] − C = 0,</formula><p><s>where C is total cortisol (µM), T is CBG (µM), U is unbound cortisol, and K is the affinity of CBG for cortisol at 37 o C <ref type="bibr" target="#b21">21</ref> .</s><s>N is the ratio of albumin bound to free cortisol, and 1.74 is the value used.</s><s>For K a value of 3x10 -7 M -1 was assumed.</s><s>This results in the formula U=(Z 2 + 0.0122*C) ½ -Z(µM) with Z=0.0167+0.182(T-C).</s><s>We did not use the free cortisol index (calculated free unbound cortisol) as published by others <ref type="bibr" target="#b22">22</ref> .</s></p><p><s>Urine steroid metabolite excretion analysis was carried out by gas chromatography/mass spectrometry as previously described <ref type="bibr" target="#b23">23</ref> .</s></p><p><s>Mitotane levels at baseline were measured as previous described, by using a gas chromatography-electron capture detection assay <ref type="bibr" target="#b24">24</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Control cohort</head><p><s>For comparison with hydrocortisone pharmacokinetics in non mitotane-treated patients we included data from a recently published prospective study <ref type="bibr" target="#b25">25</ref> investigating ten adult male patients with secondary adrenal deficiency on three different hydrocortisone regimens (20mg 8:00 + 10mg 16:00; 10mg 8:00 + 10mg 16:00; 10mg 8:00 + 5mg 16:00) and ten healthy male controls.</s><s>Measurements and analytical methods were described previously <ref type="bibr" target="#b25">25</ref> .</s><s>In addition, 24-h urines were collected in all control subjects.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses</head><p><s>Area under the curve (AUC) was calculated by using the linear trapezoid method for the study time 8:00 until 17:00.</s><s>Data are shown in mean ± SEM if not stated differently.</s><s>P-values &lt;0.05 were considered statistically significant.</s><s>Independent samples t-test was used for two groups comparison and the Mann-Whitney U test for variables which were not normally distributed.</s><s>Statistical analyses were performed using SPSS 15.0 (IBM, Armonk, NY, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Nine patients with ACC on mitotane treatment and on a stable daily immediate release hydrocortisone dose of 60mg were investigated.</s><s>The clinical characteristics of the patients are shown in Table <ref type="table" target="#tab_0">1</ref>.</s></p><p><s>Serum cortisol levels showed a wide variation in the supraphysiological range (1300-3900nmol/l) after immediate release hydrocortisone intake, and a more homogenous pattern, but unanimously much lower profile, after modified release hydrocortisone intake (570-1630nmol/l) in ACC patients (Figure <ref type="figure">1</ref>).</s><s>After 40mg of immediate release hydrocortisone intake the serum cortisol level peaked significantly higher than with 40mg modified release hydrocortisone (2105±298 vs 1015±120nmol/l; p=0.003).</s><s>The morning peak of immediate release hydrocortisone appeared one hour after the tablet intake, whereas the peak after the modified release hydrocortisone appeared two hours after tablet intake.</s><s>The AUC of the serum cortisol levels was significantly higher with immediate release hydrocortisone than with modified release hydrocortisone (10577±1393 vs 8047±1021nmol*h/l,; p=0.03).</s></p><p><s>Most of the ACC patients showed suppressed ACTH levels with no differences between the two hydrocortisone preparations (data not shown).</s></p><p><s>Urine analysis confirmed the previously described 10 enhanced cortisol metabolism with an increased CYP3A4 activity and reduced 5α-reductase activity, and an overall increased total glucocorticoid excretion in our ACC patients on mitotane (Table <ref type="table" target="#tab_1">2</ref>).</s></p><p><s>Most of the cortisol (80-85%) is bound to the specific binding protein corticosteroid binding globulin (CBG), approx.</s><s>10% to albumin and the remaining is present in the free form.</s><s>It is assumed that the bioavailability of endogenous glucocorticoids is predominantly influenced by CBG, and in situations where CBG levels are altered, e.g.</s><s>mitotane treatment, total cortisol levels may not adequately represent the free cortisol fraction.</s><s>It is assumed that the biologically active level of cortisol to which tissues are exposed is free cortisol.</s><s>Therefore we measured CBG, and showed that serum CBG levels in ACC patients were high (median 2.50 µmol/l).</s><s>By correcting for the sex-specific upper-limit of the normal range, the CBG levels were 1.36-(0.87-3.0)</s><s>fold (mean (range)) above sex-specific upper-limit of normal.</s></p><p><s>In ACC patients, calculated free cortisol levels showed more pronounced peaks (12-144nmol/l) after tablet intake of immediate release hydrocortisone (Figure <ref type="figure">2a</ref>), whereas the peaks were blunted after intake of modified release hydrocortisone (5-33nmol/l) (Figure <ref type="figure">2b</ref>).</s><s>This resulted in significant, fourfold higher mean free cortisol levels after immediate release than after modified release hydrocortisone intake (46±14 vs 12±3nmol/l; p=0.03) (Figure <ref type="figure" target="#fig_1">3a</ref>).</s></p><p><s>For comparison with immediate release hydrocortisone pharmacokinetics in non mitotane-treated patients, we included data from ten adult male with secondary adrenal insufficiency and ten healthy controls.</s><s>In men with secondary adrenal insufficiency, a morning dose of immediate release hydrocortisone resulted in a mean free cortisol level of 64±16nmol/l (10mg dose) and 128±22nmol/l (20mg dose), respectively (Figure <ref type="figure" target="#fig_1">3b</ref>).</s><s>Physiological morning free cortisol levels peaked around 31±5nmol/l in ten healthy men (Figure <ref type="figure" target="#fig_1">3b</ref>).</s></p><p><s>The AUC of the calculated free cortisol levels was significantly higher with immediate release hydrocortisone than with modified release hydrocortisone (149±37 vs 98±21nmol/l/h, respectively; p=0.02).</s><s>Compared to the available data from men with secondary adrenal insufficiency, the AUC of the calculated free cortisol levels during treatment of immediate release hydrocortisone was slightly higher in ACC patients under mitotane than the AUC achieved by a 10mg-10mg-0mg treatment in secondary male AI patients but lower than values achieved by a 20mg-10mg-0mg regime.</s><s>The AUC of calculated free cortisol levels with 40-20-0mg modified release hydrocortisone (70±11nmol/l) resembled the levels achieved by a 10mg-5mg immediate release hydrocortisone regimen in male secondary AI patients (114±14nmol).</s></p><p><s>Salivary cortisol levels showed large variations after tablet intake and reached very high levels in some patients (Figure <ref type="figure" target="#fig_2">4</ref>), exceeding normal salivary cortisol morning levels (1.3-25.7nmol/l)</s><s>20-50-fold.</s><s>No significant difference in salivary cortisol levels was observed between immediate or modified release hydrocortisone intake.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The main finding in our ACC patient group with mitotane treatment is that modified release hydrocortisone resulted in much lower total and free cortisol levels than immediate release hydrocortisone despite the administration of identical doses.</s><s>In addition, modified release hydrocortisone in ACC patients lacked the physiological morning free cortisol peak seen in healthy subjects.</s><s>In contrast, immediate release hydrocortisone in ACC patients provided a similar morning free cortisol peak as seen in healthy males and in males with secondary adrenal insufficiency with a 10mg immediate release hydrocortisone morning dose <ref type="bibr" target="#b25">25</ref> .</s></p><p><s>In a previously published pharmacokinetic study with modified release hydrocortisone the time to reach a clinically significant plasma concentration of cortisol (&gt;200 nmol/l) was within 20 min and a mean peak of 431 nmol/l was obtained within 50 min after administration of the 20 mg tablet <ref type="bibr" target="#b18">18</ref> .</s><s>A 20mg tablet at a fasted state resulted in an AUC of 3634 nmol*h/l in healthy subjects <ref type="bibr" target="#b18">18</ref> .</s><s>In comparison to that study, here we administered the three-fold dose of modified release hydrocortisone in our patients and received a mean AUC of 8047 nmol*h/l.</s><s>The slightly lower than expected rate might be explained by the fact that the absorption and bioavailability is not fully dose proportional.</s><s>This is most likely due to reduced dissolution rate kinetics of hydrocortisone in the intestinal lumen at the higher dose that will in turn reduce the absorption rate <ref type="bibr" target="#b18">18</ref> .</s><s>In addition, we studied ACC patients on mitotane treatment and not healthy volunteers.</s><s>Mitotane is known to have a wide range of gastrointestinal side effects <ref type="bibr" target="#b26">26</ref> possibly influencing intestinal hydrocortisone absorption.</s><s>Furthermore CYP3A4 induction by mitotane results in rapid inactivation of more than 50% of administered hydrocortisone, explaining the need for at least doubling of the hydrocortisone replacement dose in mitotane-treated patients to achieve a comparable glucocorticoid exposure as is reached in subjects not treated with CYP3A4 inducing compounds <ref type="bibr" target="#b9">10</ref> .</s><s>Comparing mean serum total cortisol AUC of immediate and modified release hydrocortisone in ACC patients on mitotane resulted in a trend to lower AUC for modified release hydrocortisone (10577±4179 nmol/l*h vs. 8047±3066 nmol/l*h, p=0.163), suggesting that glucocorticoid exposure achieved by modified release hydrocortisone might be lower compared to immediate release hydrocortisone.</s><s>This difference is similar to what has been observed in patients with Addison's disease receiving either glucocorticoid replacement.</s></p><p><s>Interestingly, the total levels of cortisol achieved by a treatment with 40-20-0 immediate release regimen are high (Figure <ref type="figure">1</ref>), suggesting that daily doses of 40-50mg of immediate release hydrocortisone might be sufficient.</s><s>However, this dose reduction would not be justified by our observation that free cortisol levels were comparable to the levels obtained with a 10mg immediate release morning dose in patients with adrenal insufficiency (Figure <ref type="figure">2</ref>-3) <ref type="bibr" target="#b25">25</ref> .</s><s>In general, deduced from the cortisol levels measured in these patients, glucocorticoid coverage was achieved by the 40-20-0mg immediate release hydrocortisone regimen which may be regarded as sufficient and without cortisol trough levels below a value that would pose a safety issue.</s></p><p><s>In case of administration of modified release hydrocortisone, a once daily administration is generally recommended.</s><s>On the background of the rapid metabolic inactivation of cortisol due to increased CYP3A4 activity by mitotane, we assumed that a once daily regime might not be sufficient to secure sufficient glucocorticoid coverage over the whole day and decided to test a twice daily regimen.</s><s>However, considering our measurements we believe that even a 40mg-20mg-0mg modified release hydrocortisone regimen did not provide sufficient free cortisol levels in mitotane treated ACC patients.</s><s>Salivary cortisol is regarded as CBG-independent measurement reflecting the free serum cortisol.</s><s>Therefore.</s><s>it is thought to be a good tool to monitor glucocorticoid replacement therapy in ACC patients on mitotane.</s><s>Our results show massively increased salivary cortisol levels with a 40mg-20mg-0 hydrocortisone replacement therapy in ACC patients on mitotane.</s><s>A recent study showed that the ECLIA immunoassay possesses a quite large cross-reactivity with endogenous cortisol precursors and metabolites, especially with 6β-hydroxycortisol (148% cross reactivity) <ref type="bibr" target="#b27">27</ref> , the main cortisol metabolite in mitotane treated patients.</s><s>Therefore, we believe that our salivary results are influenced and overestimated by this crossreactivity.</s><s>This is endorsed by another study showing a significant difference in salivary cortisol levels measured with the ECLIA method and LC-MS/MS <ref type="bibr" target="#b28">28</ref> .</s></p><p><s>Therefore we suggest that salivary cortisol levels should be measured only with LC-MS/MS in mitotane treated ACC patients.</s></p><p><s>It must be taken into account that both replacement regimes were tested only for one day, and we do not have data on longer treatment periods with modified release hydrocortisone in mitotane-treated ACC patients.</s><s>However, it would be interesting to further investigate patient acceptance and quality of life in mitotane treated ACC patients depending on the form of hydrocortisone replacement therapy.</s><s>In addition, a longer duration of observation would have provided information on the impact of potential gastrointestinal effects of mitotane on hydrocortisone kinetics.</s><s>Longer study durations must also include safety aspects such as the frequency of adrenal crisis in those patients.</s><s>The relevance of the lacking morning cortisol peak and the low free cortisol levels during the day in ACC patients treated with modified release hydrocortisone further remains to be clarified.</s></p><p><s>In conclusion, here we show that immediate release but not modified release hydrocortisone at a dose of 60mg per day result in sufficient glucocorticoid coverage in patients with ACC under mitotane treatment.</s><s>Glucocorticoid exposure in mitotanetreated patients receiving modified release hydrocortisone appears to be considerably lower compared to the same dose of immediate release hydrocortisone, suggesting that the use of equivalent doses of modified release hydrocortisone preparation should be avoided in patients on mitotane treatment.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 :Figure 2 :</head><label>12</label><figDesc><div><p><s>Figure 1: Serum-Cortisol in nine ACC patients on mitotane receiving 40mg (8.00)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 3 :</head><label>3</label><figDesc><div><p><s>Figure 3: Mean calculated free serum cortisol (nmol/l) in a) nine ACC patients on</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 4 :</head><label>4</label><figDesc><div><p><s>Figure 4: Mean salivary cortisol (nmol/l) in nine ACC patients on mitotane receiving</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 :</head><label>1</label><figDesc><div><p><s>Patients´ characteristics Median (Range).</s><s>BMI, body mass index; ACC, adrenocortical cancer; SAI, secondary adrenal insufficiency.</s><s>na = not available</s></p></div></figDesc><table><row><cell>Characteristics</cell><cell>ACC patients</cell><cell>SAI patients</cell><cell>Healthy</cell></row><row><cell></cell><cell></cell><cell></cell><cell>controls</cell></row><row><cell>Male/female</cell><cell>6/3</cell><cell>10/0</cell><cell>10/0</cell></row><row><cell>Age (years)</cell><cell>54 (27-75)</cell><cell>48 (26-71)</cell><cell>45 (27-67)</cell></row><row><cell>Time since diagnosis</cell><cell>44 (6-192)</cell><cell>na (36-216)</cell><cell>-</cell></row><row><cell>(months)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>BMI (kg/m 2 )</cell><cell>24.0 (17.2-33.3)</cell><cell>28.4 (25.4-40.1)</cell><cell>28.3 (25.3-38.5)</cell></row><row><cell>Duration of mitotane</cell><cell>34 (6-87)</cell><cell>-</cell><cell>-</cell></row><row><cell>treatment (months)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Daily mitotane dose (mg)</cell><cell>1500 (0-2500)</cell><cell>-</cell><cell>-</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 :</head><label>2</label><figDesc><div><p><s>24-hour urine analysis by gas chromatography/mass spectrometry in 9 adrenocortical cancer (ACC) patients on mitotane, 10 male patients with secondary adrenal insufficiency (SAI) on different hydrocortisone (HC) dose regimen, and 10 healthy male subjects.</s><s>F = cortisol; THF = tetrahydro-cortisol.</s><s>Means ± SD.</s></p></div></figDesc><table /></figure>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Adrenal cortical carcinoma in Norway, 1970-1984</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Soreide</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Brabrand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Thoresen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Surg</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="663" to="667" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Adrenocortical carcinoma</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Brennan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CA Cancer J Clin</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="348" to="365" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Adrenocortical carcinoma: Past, present, and future</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lafemina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Brennan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Surg Oncol</title>
		<imprint>
			<biblScope unit="page">10</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Adrenal cortical carcinoma</title>
		<author>
			<persName><forename type="first">M</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boileau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">V</forename><surname>Hodges</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Urol</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="660" to="665" />
			<date type="published" when="1978">1978</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel</title>
		<author>
			<persName><forename type="first">A</forename><surname>Berruti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fassnacht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Baudin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hammer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Haak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Leboulleux</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="e401" to="e402" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Mitotane for adrenocortical carcinoma treatment</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hahner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fassnacht</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Investig Drugs</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="386" to="394" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Adjuvant mitotane treatment for adrenocortical carcinoma</title>
		<author>
			<persName><forename type="first">M</forename><surname>Terzolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Angeli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fassnacht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Daffara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tauchmanova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Conton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">356</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="2372" to="2380" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells</title>
		<author>
			<persName><forename type="first">S</forename><surname>Sbiera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Leich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Liebisch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Sbiera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schirbel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wiemer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocrinology</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="3895" to="3908" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Mitotane has a strong and a durable inducing effect on CYP3A4 activity</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Van Erp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Guchelaar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Ploeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Romijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hartigh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gelderblom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Endocrinol</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="621" to="626" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5alpha-reductase, explaining the need for personalized glucocorticoid and androgen replacement</title>
		<author>
			<persName><forename type="first">V</forename><surname>Chortis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Tomlinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>O'neil</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="161" to="171" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">I</forename><surname>Alexandraki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Kaltsas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Le Roux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fassnacht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ajodha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Christ-Crain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Endocrinol (Oxf)</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="305" to="311" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Adrenocortical Carcinoma: Clinical Update</title>
		<author>
			<persName><forename type="first">B</forename><surname>Allolio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fassnacht</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Haak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hermans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Lentjes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Goslings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Fleuren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="947" to="951" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Hepatic microsomal enzyme induction and adrenal crisis due to o,p&apos;DDD therapy for metastatic adrenocortical carcinoma</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">V</forename><surname>Hague</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>May</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Cullen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Endocrinol (Oxf)</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="51" to="57" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kroiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Quinkler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Lutz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Allolio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fassnacht</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Endocrinol (Oxf)</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="585" to="591" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Mitotane increases the blood levels of hormone-binding proteins</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Van Seters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Moolenaar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Endocrinol (Copenh)</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="526" to="533" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title level="m" type="main">Long-acting hydrocortisone for glucocorticoid replacement therapy</title>
		<author>
			<persName><forename type="first">G</forename><surname>Johannsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Filipsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bergthorsdottir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lennernas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Skrtic</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Horm Res</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="182" to="188" />
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Johannsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bergthorsdottir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Nilsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lennernas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hedner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Skrtic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Endocrinol</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="119" to="130" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation</title>
		<author>
			<persName><forename type="first">G</forename><surname>Johannsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Nilsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bergthorsdottir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Burman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dahlqvist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ekman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="473" to="481" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Modifiedrelease hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency</title>
		<author>
			<persName><forename type="first">M</forename><surname>Quinkler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Miodini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zopf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ventz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Oksnes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Endocrinol</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="619" to="626" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Clinical use of unbound plasma cortisol as calculated from total cortisol and corticosteroid-binding globulin</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Coolens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Van</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Heyns</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Steroid Biochem</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="197" to="202" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">The use of free cortisol index for laboratory assessment of pituitary-adrenal function</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Bonte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Van Den Hoven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Vermes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem Lab Med</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="127" to="132" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors</title>
		<author>
			<persName><forename type="first">W</forename><surname>Arlt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Biehl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hahner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Libe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Hughes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="3775" to="3784" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Estimation of o,p&apos;-DDD in plasma by gas-liquid chromatography</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Moolenaar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Niewint</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">T</forename><surname>Oei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chim Acta</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="213" to="218" />
			<date type="published" when="1977">1977</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin-deficient hypopituitary male patients</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Behan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Hannon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>O'kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Tormey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Endocrinol (Oxf)</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="505" to="513" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Update in adrenocortical carcinoma</title>
		<author>
			<persName><forename type="first">M</forename><surname>Fassnacht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kroiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Allolio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="4551" to="4564" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Krasowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Drees</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Maakestad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Blau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ekins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="33" to="47" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Assessment of salivary free cortisol levels by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in patients treated with mitotane</title>
		<author>
			<persName><forename type="first">C</forename><surname>Carrozza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lapolla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gervasoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Rota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Locantore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pontecorvi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hormones (Athens )</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="344" to="349" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
